Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

How to decrease the non-compliance in a clinical trial.

G M Baratelli1, W Allio, A Lanzani

  • 1Delegazione Alto Lario della Lega Italiana per la Lotta contro i Tumori, Gravedona, Como, Italy. gm.bar@usa.net

Minerva Medica
|February 19, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[<sup>18</sup>F]FDG PET/MRI vs sentinel node biopsy for axillary staging of early breast cancer patients. A prospective single-arm trial.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Negative symptom severity at discharge from an index hospitalization and subsequent use of psychiatric care resources: A retrospective 1-year follow-up study on 450 patients with schizophrenia spectrum disorders.

Schizophrenia research·2019
Same author

Do dogs exhibit jealous behaviors when their owner attends to their companion dog?

Animal cognition·2018
Same author

Improved prognosis of young patients with breast cancer undergoing breast-conserving surgery.

The British journal of surgery·2017
Same author

The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis.

The pharmacogenomics journal·2016
Same journal

Smoking, healthy lifestyle and adolescence.

Minerva medica·2026
Same journal

How to become a centenarian in four weeks?. Myths and limits of longevity recipes: a critical review.

Minerva medica·2026
Same journal

Comparative efficacy and safety between intravenous recombinant human prourokinase and alteplase in acute ischemic stroke treatment: a meta-analysis of randomized controlled trials.

Minerva medica·2026
Same journal

Efficacy and safety of oral tapentadol for cancer-related pain: an updated systematic review and meta-analysis.

Minerva medica·2026
Same journal

Use of the neurostimulator in thyroidectomy procedures: comparison between vagal and recurrent laryngeal nerve stimulation.

Minerva medica·2026
Same journal

Iron deficiency and risk of acute kidney injury after TAVI: a machine learning analysis.

Minerva medica·2026
See all related articles

Achieving high participant compliance in clinical trials is crucial. This study highlights a successful strategy for improving compliance in the Italian Tamoxifen Prevention Study, significantly reducing non-compliance rates.

Area of Science:

  • Clinical Trials
  • Oncology
  • Preventive Medicine

Background:

  • High participant compliance is essential for multicenter clinical trials and ethical conduct.
  • Compliance issues can stem from recruitment quality or follow-up organization.

Purpose of the Study:

  • To illustrate the strategies employed to achieve high participant compliance.
  • Focus on the Operative Center in Gravedona for the Italian Tamoxifen Prevention Study.

Main Methods:

  • Implementing a specific policy for participant recruitment and follow-up.
  • Detailed organizational procedures for maintaining participant engagement.

Main Results:

  • The Operative Center achieved a significantly low non-compliance rate of 5.6%.

Related Experiment Videos

  • This contrasts sharply with the overall trial non-compliance rate of 23.3%.

    • Conclusions:

    • The adopted policy effectively enhances participant compliance in clinical trials.
    • Demonstrates the success of targeted strategies in improving trial integrity.